Our foremost priorities through the pandemic have been delivering critical supplies and medications, and protecting our employees, many whom are on the frontline. And attempting to clear up what it considered to be misunderstandings.This past year was a year unlike any other - one where our mission of improving care in every setting - one product, one partner, one patient at a time - has never been more important. Pre-Printed Label Comply Printer Label White Tape Sterilized Blue Sterilization Label 1-29/50 X 2-17/20 cm.The procedure essentially checks all claims directed to statutory subject. Log In to Order View Alternatives. Log in for pricing and availability. Pre-Printed Label Comply Laboratory Use White Tape Sterilized Red Sterilization Label 5/8 X 1-1/8 Inch.
Despite the challenges presented by the past year, the Company made significant progress executing against strategic growth initiatives while adapting to near-term uncertainties. We thank you for your investment in McKesson and for your confidence in McKesson's employees, management team and Board. As a Board, we recognize that we have been elected by you to oversee and help ensure the long-term success and sustainability of McKesson's business for the benefit of all stakeholders.
On behalf of all of the members of the Board, we wish them well and want to thank them for their years of dedicated service.We also welcomed Linda Mantia, former senior executive vice president and chief operating officer of Manulife Financial Corporation, as our newest independent director and member of the Board's Audit and Governance Committees. Additionally, Tony Coles informed the Board in April that he will not stand for reelection this year. Chris Jacobs and Marie Knowles, our two longest-serving directors, will not be standing for reelection at the 2021 Annual Meeting.
Some of the measures we have taken in response to the COVID-19 pandemic include: Throughout the pandemic, we have taken steps to advance public health goals, maintain essential access to medications and supplies for our customers, and safeguard our employees from the spread of COVID-19. Additionally, we have partnered with government agencies at the federal, state and local level, along with other industry leaders, to help find solutions to the most complex and pressing issues the crisis presented. Experts at every level within our organization mobilized to address new developments as they occurred and interacted with regulatory authorities around the world to help ensure we were well prepared to address our customers' evolving needs, so that they can, in turn, care best for their patients. If the Board decides it is in the best interests of the Company and its shareholders to reject a resignation, the Board will disclose its rationale.When the scale of the COVID-19 pandemic began to crystallize in early 2020, the Board collaborated with management to help ensure the stability of our critical services to our customers and protection of our employees.
Pharmaceutical Supply Chain: Protecting and ensuring the supply of medications for healthcare providers McKesson is also playing a role in vaccine distribution in Canada and certain jurisdictions in Europe Government as the centralized distributor of COVID-19 vaccines and ancillary supply kits. Vaccine Distribution: Supporting the U.S.
Our Board, which has long believed that oversight of the Company's culture and reputation are key Board responsibilities, works with management to establish and communicate the right ethical tone, which guides our conduct and helps protect the Company's reputation. We take our role in risk oversight seriously, including on matters related to controlled substances. Our Board is dedicated to cultivating a culture focused on integrity and accountability. McKesson will continue to be part of the recovery, serving our customers and partners every step of the way.At McKesson, the way we do business is just as important as the business itself, and doing business in the right way continues to be fundamental to, and embedded in, our culture. The Board is proud to see that our approach to addressing the pandemic has been consistent with our vision to improve care in every setting.
As we have previously disclosed, in May 2018, the Compensation Committee reinforced and codified its longstanding practice of considering the impact of regulatory, compliance and legal issues when making executive compensation decisions. We remain hopeful that a broad resolution can be achieved, which would accelerate relief efforts for the people and communities impacted by this public health crisis. In the third quarter of FY 2021, we made an accrual of approximately $8.1 billion, reflecting McKesson's estimated liability over a period of 18 years for those opioid-related claims. McKesson is in ongoing advanced discussions regarding opioid-related claims of governmental entities and based on the substantial progress we have made toward a broad settlement of those claims, we determined it was appropriate to accrue for this potential liability.
As we reflect on FY 2021, our results reflect McKesson's ability to rise to the challenge and meet the evolving demands of our customers and partners, and demonstrate continued execution against our priorities: strong operating profit performance, promoting an inclusive culture and streamlining McKesson's portfolio. McKesson focused on building out a connected ecosystem over the last several years in the areas of oncology and biopharma services where we believe we have key differentiated capabilities. We are actively engaged in reviewing, guiding and overseeing the development and the execution of these value- creation strategies. Please refer to page 35 of our Compensation Discussion & Analysis to learn more.Among the Board's stewardship functions, providing oversight related to McKesson's near- and long-term strategies is paramount.
We look forward to hearing your views at this year's annual meeting and in the year to come.Your vote is very important to us. We appreciate the opportunity to serve McKesson on your behalf in 2021 and beyond, and will continue our focus on the sustainable and long-term growth of the Company. This dialogue provides us with valuable insight and feedback from shareholders on an ongoing basis, allowing the Board to better understand our shareholders' priorities and perspectives and to incorporate them into our deliberations and decision-making.We value the trust you place in us through your investment in McKesson. Our robust program, which includes director participation, meets with a broad base of shareholders throughout the year to discuss corporate governance, executive compensation, sustainability and ESG practices, and other matters of importance.
0 kommentar(er)
